Interferon

K. Gowin, P. Thapaliya, J. Samuelson, C. Harrison, D. Radia, B. Andreasson

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients 

Haematologica 2012; 97(10): 1570-1573.

H. C. Hasselbalch, J.-J. Kiladjian, R. T. Silver

Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Journal of Clinical Oncology 2011; 29(18): 564-e565

J-J. Kiladjian,B.Cassinat,S. Chevret,P. Turlure,N. Cambier, M.Roussel

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Blood 2008; 112: 3065-3072

Ch. Langer, E. Lengfelder, J. Thiele, H. M. Kvasnicka, H.L. Pahl, H. Beneke

Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study

Haematologica 2005; 90: 1333-1338

W. Linkesch, H. Gisslinger, H. Ludwig, R. Flener, H. Sinziger

Therapie mit Interferon (rekombinantes IFN-alfa-2C) bei myeloproliferativen Erkrankungen mit exzessiven Thrombozytosen 

Acta med.Austriaca 1985; 123-127

J. Samuelsson, H. Hasselbalch, O. Bruserud, S. Temerinac, Y. Brandberg, M. Merup

A Phase II Trial of Pegylated Interferon alfa-2b Therapy for Polycythemia Vera and Essential Thrombocythemia

Cancer 2006; 106: 2397– 405.